Shocking in the healthcare venture capital scene! 100 female entrepreneurs have created 30 IPOs, securing nearly 10 billion in funding

Article | Medical Insight, Author | Zhang Xiaoman

For a long time, in traditional beliefs and even stereotypes, the healthcare sector—especially high-end medical devices, innovative drugs, and AI medical technologies—has been regarded as an “absolutely male-dominated” territory.

Women in medical companies are often subjectively stereotyped as CFOs, HR directors, or limited to consumer healthcare and service sectors that focus more on business model innovation.

However, after a comprehensive review by Medical Insight, it is found that more and more female entrepreneurs are emerging in the healthcare industry.

Not only that, but among them, over 30 have successfully led their companies to IPO, with footprints across core capital markets such as A-shares, Hong Kong, and the US.

At the same time, in the primary market, at least 70 female entrepreneurs have secured nearly 10 billion RMB in funding.

What’s more noteworthy is that the vast majority of these women are not professional managers but are also serving as chief scientists or R&D presidents, leading the underlying technology.

It can be said that these 100 female entrepreneurs are industry disruptors, wave-makers, insight-givers, and stealth players. Through fierce competition, they have carved out a path, defining the next golden decade for China and even the global healthcare industry.

On the occasion of International Women’s Day 2026, this article will analyze this powerful “she-force” shaking up the medical venture capital scene, along with the underlying industry logic.

01 Disruptors, Navigating the “No Man’s Land” of Hard Technology

For a long time, implantable consumables, large life-support equipment, and cutting-edge bioengineering have been regarded as “male engineers’ exclusive domain” due to their crossing of highly obscure interdisciplinary fields such as fluid mechanics, precision machinery, microelectronics, and neuroscience.

But when we look into these frontier medical companies, we find that more and more women are making significant contributions at the technological core.

Across the ocean, Elon Musk’s Neuralink has attracted global attention, attempting to monopolize the discourse on “brain-machine interfaces.” In China, Li Xue, founder and CEO of Ladder Medical, is a pioneer in the brain-machine interface field.

With a large Series B funding of 350 million RMB, she is leading her team to build a high-bandwidth information channel between the human brain and computers using ultra-micro invasive flexible microelectrodes—created by Chinese female scientists—directly challenging international giants.

In the precise cardiovascular defense sector, Xu Boling, founder and CEO of XinQing Medical, demonstrates the ultimate hardcore spirit of women. With a solid background in fluid mechanics and biomedical engineering, she has broken through the technical black box of “artificial hearts” and extracorporeal life support devices.

Facing extremely complex blood compatibility and fluid control barriers, she has secured over 100 million RMB in Series C funding with rigorous engineering data, seizing the “time window” for global heart failure patients to cross life and death.

Turning to the micro world, Yang Luhan, founder and CEO of Qihan Biological, is regarded as a “genetic magician.” As a top global gene editing scholar, she focuses on the century-old challenge of xenotransplantation, securing multiple rounds of over one hundred million USD in funding.

They do not need to promote themselves with slogans of gender equality; instead, they continuously achieve breakthroughs in what is called the “no man’s land” of scientific research, greatly contributing to China’s medical innovation and upgrading.

02 Wave-Makers, Going Global and Turning the Tide

If bottom-layer innovation requires a geek spirit, then facing the unpredictable changes in the pharmaceutical industry and crossing multinational giants demand fierce tactics and unparalleled strategic resolve.

On the high-stakes table of innovative drugs worth hundreds of billions, female leaders have shown a strategic and wave-breaking vision.

In the arena of drug globalization, Xia Yu, founder and chairman of Kangfang Biotech, is the undisputed “Queen of Bispecific Antibodies.” With over 20 years of experience at top overseas universities and multinational pharmaceutical companies, she established Kangfang with a strict rule: “Only First-in-Class.”

Everyone in the pharma circle knows that daring to conduct head-to-head, double-blind efficacy trials of new drugs against global giants is a huge business gamble—any misstep could impact the company profoundly.

But Xia Yu dared to gamble—and won. In 2024, her lead candidate, Ivosimab, defeated Merck’s renowned cancer drug Keytruda in a globally watched Phase III trial, shocking the medical world.

This victory not only set a record for a single overseas licensing deal worth billions of dollars but also boosted Kangfang’s market value to over HKD 50 billion. Xia Yu’s data proves to the world that China’s original biopharmaceuticals have the strength to confront multinational giants head-on.

Meanwhile, in macro policy cycles, the “elephant turning” of female entrepreneurs is equally decisive.

Zhong Huijuan, founder and chairwoman of Hansoh Pharma, is undoubtedly one of the most legendary operators in this history. In an era when generics could still earn easy profits, she keenly sensed danger.

On the eve of national “collective procurement,” Zhong Huijuan used swift and decisive actions, years ahead of others, to reverse the course of this giant ship and heavily invest in innovative drug R&D.

Today, Hansoh ranks among the Hong Kong stock giants with a market cap of hundreds of billions, with blockbuster drugs like Amisulpride as key revenue pillars.

Facing the need to go global and the necessity of strategic shifts, top business leaders demonstrate such resolve. Female entrepreneurs possess the same strength.

03 Insight Givers, Deep Empathy and Precise Market Judgment

Great business models often stem from the deepest empathy.

In past healthcare investments, male entrepreneurs tended to chase hot targets and grand narratives; female entrepreneurs, however, excel at getting close to real patients, overlooked healthcare workers, and unmet edge needs.

Ma Chun’e, founder and CEO of Shikun Technology, was motivated by a “pain point” to cross into AI healthcare. As a former top engineer at IBM, she saw patients waiting anxiously overnight for diagnosis and radiologists exhausted by reviewing massive black-and-white films.

Driven by empathy to genuinely help doctors reduce burdens, she created the “Digital Human Body” platform, pioneering AI applications in complex cardiovascular and cerebrovascular imaging diagnostics, securing over 2 billion RMB in funding from Sequoia and others, and striving for IPO.

Similarly, Guan Yuxiu, chairwoman of Kuaishou Pharmaceutical, deeply understands the plight of pediatric medicine—“lack of medical resources and reliance on guesswork for dosing.” She built a vast pediatric drug portfolio, carving out a deep moat in the red ocean.

Even more explosive are the super queens of China’s “beauty economy” and new materials sectors.

According to Medical Insight, in aesthetic medicine and synthetic biology, nearly all leading companies are founded by women: Zhao Yan of Huaxi Biological, Jian Jun of Aimeike, Fan Daidi of Juzi Biotech, Yang Xia of Jinbo Biotech. These “Four Swords of Medical Aesthetics” precisely capture modern women’s deep psychological needs for “self-pleasure and anti-aging.”

The outside world often marvels at the profitability of this sector but overlooks that they are integrating cutting-edge microbial fermentation, recombinant humanized collagen, and other hardcore underlying technologies with vast consumer demand. They have built several billion-dollar market cap empires, successfully listed on capital markets, and continuously grow amid fierce competition.

They understand better than anyone: understanding human nature is itself a top-tier technological realization.

04 Stealth Players, Navigating Capital Cycles with Extreme Pragmatism

The past three years of the healthcare capital winter have challenged countless entrepreneurs. Some founders struggled with valuation mismatches, willing to see their companies go bankrupt and pipelines abandoned rather than compromise.

At the edge of life and death, female leaders have shown awe-inspiring business rationality—willing to give up personal obsessions to preserve their teams and vital pipelines.

During the hottest period of ADC overseas expansion and at the most difficult point for domestic biotech financing, Qin Ying, founder of Lixin Medical, made a decision that stunned the industry. Facing costly clinical R&D, she chose not to stubbornly pursue an independent IPO in the primary market but to align with mature commercial logic and accept a substantial acquisition of about 500 million USD by China’s biopharmaceutical giant.

Abandoning the halo of independence for abundant funds to continue clinical development and benefit patients—this is a courageous act of strategic restraint based on absolute rationality.

Among this list, the most poignant and admirable is the choice made by Wang Yuxiao, CEO of Chunyu Doctor.

As a pioneer in China’s mobile healthcare, Chunyu Doctor was valued near USD 1 billion. When founder Zhang Rui suddenly died of a heart attack in 2016, the company was plunged into chaos.

Faced with years of relentless pressure from internet giants crushing the healthcare ecosystem and prolonged profitability struggles, Zhang Rui’s widow, Wang Yuxiao, stepped from behind the scenes to the forefront, shoulders bearing the weight of a platform with over 100 million users.

By late 2025, an announcement shook the industry: Chunyu Doctor was acquired by Hong Kong-listed property company Guorui Life for 269 million RMB.

From a former valuation of hundreds of millions to a “discounted sale,” skeptics might mock. But industry insiders know that in the brutal winter of mobile healthcare, Wang Yuxiao did not let the company go bankrupt nor delay doctors’ fees. Instead, she explored a “community + healthcare” model by integrating physical properties, finding a solid foothold for survival for her team and tens of thousands of doctors.

To preserve the big picture and be responsible for life, swallowing all grievances and doubts—this is the ultimate pragmatic business spirit.

05 An Irreplaceable “Her Era”

Besides the entrepreneurs mentioned above, many women are rooted in various subfields of healthcare, making outstanding contributions. Due to space limitations, they cannot all be listed here.

But with 30 IPOs and nearly 10 billion RMB in funding, the market’s recognition and emphasis on female strength are evident— in this high-risk, high-technical barrier, long-cycle industry, women’s traits have become the most scarce and valuable business moat.

Today, what do investors value most?

Extreme cash flow sensitivity, strategic focus on core pipelines, deep empathy for unmet clinical needs, and pragmatic resilience in extreme cycles—being flexible and not obsessed with illusory valuations.

And this, precisely, is the absolute domain of female entrepreneurs. The primary market calls it the “resilience premium” belonging to women.

On this special day, March 8, 2026, Medical Insight pays tribute to all outstanding women, including 100 entrepreneurs: from microscopic reactions in antigen test reagents to every powerful pump of artificial hearts; from CAR-T cells deep in the marrow to AI-driven efficiency improvements—her name is deeply imprinted in every core, hardcore artery of China’s and the global healthcare industry chain.

It’s no exaggeration to say that in the endless journey of healthcare innovation, “her power” has become the strongest engine driving humanity across the abyss of disease toward health and longevity.

And we will continue to witness their more magnificent and turbulent next golden decade.